| Not Yet Recruiting | Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progre NCT07001995 | Hunan Province Tumor Hospital | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigen NCT06694454 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Not Yet Recruiting | QLS5132 Combination Therapy in Advanced Solid Tumors NCT07453394 | Qilu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors NCT07517198 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants Wi NCT07361497 | Bristol-Myers Squibb | Phase 3 |
| Recruiting | A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated A NCT07361510 | Bristol-Myers Squibb | Phase 3 |
| Recruiting | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NCT07277413 | IDEAYA Biosciences | Phase 1 |
| Not Yet Recruiting | Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT07435038 | Betta Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494 | Essen Biotech | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for R NCT07169708 | Ono Pharmaceutical Co., Ltd. | — |
| Recruiting | Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer NCT07288177 | Genmab | Phase 2 |
| Recruiting | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors NCT07397338 | Revolution Medicines, Inc. | Phase 1 / Phase 2 |
| Recruiting | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors NCT07349537 | Revolution Medicines, Inc. | Phase 1 |
| Not Yet Recruiting | Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety St NCT07365410 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | The Construction and Clinical Application of an Integrated Perioperative Management System for Lung Cancer Bas NCT07310056 | West China Hospital | N/A |
| Not Yet Recruiting | A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer NCT07338396 | Guangzhou University of Traditional Chinese Medicine | — |
| Recruiting | Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab NCT07510724 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | — |
| Not Yet Recruiting | A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Pa NCT07283198 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2 |
| Recruiting | Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for P NCT07276789 | Integro Theranostics | Phase 2 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Ca NCT07223047 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Not Yet Recruiting | Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis NCT07246759 | OncoHost Ltd. | — |
| Recruiting | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer NCT07227168 | Sutro Biopharma, Inc. | Phase 1 |
| Recruiting | Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Me NCT07291037 | AstraZeneca | Phase 3 |
| Recruiting | A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC NCT07206498 | Wayshine Biopharm, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable S NCT07197853 | Xin Ye | Phase 3 |
| Not Yet Recruiting | Athletic Intervention After THoracic surgEry for luNg cAncer: a Pilot Study NCT07159646 | Fondazione IRCCS Policlinico San Matteo di Pavia | N/A |
| Recruiting | A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) NCT07140016 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Recruiting | Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors NCT07151040 | One-carbon Therapeutics AB | Phase 1 / Phase 2 |
| Recruiting | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) NCT07154706 | Nuvation Bio Inc. | Phase 3 |
| Recruiting | Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thorac NCT06680050 | Mario Negri Institute for Pharmacological Research | Phase 2 |
| Recruiting | Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC NCT06897046 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Not Yet Recruiting | A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors NCT07036185 | Shanghai Bao Pharmaceuticals Co., Ltd. | Phase 1 |
| Completed | A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC NCT07141563 | Bristol-Myers Squibb | — |
| Recruiting | PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC NCT06977074 | Sun Yat-sen University | Phase 2 |
| Recruiting | A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advan NCT07172802 | GI Innovation, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521 | Tanabe Pharma America, Inc. | Phase 1 / Phase 2 |
| Recruiting | Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI NCT07087223 | Peking University Cancer Hospital & Institute | Phase 1 / Phase 2 |
| Recruiting | Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT06895031 | Guangzhou JOYO Pharma Co., Ltd | Phase 2 |
| Active Not Recruiting | KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors NCT06767046 | Corregene Biotechnology Co., Ltd | Phase 1 |
| Recruiting | A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC NCT06754930 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) NCT06710132 | EMD Serono Research & Development Institute, Inc. | Phase 1 / Phase 2 |
| Recruiting | Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer NCT06889467 | Barzilai Medical Center | — |
| Recruiting | The Role of DNA and RNA in NGS Analyses for Advaced Stage NSCLC Patients NCT07188480 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | N/A |
| Not Yet Recruiting | A Study on the Efficacy of Immunotherapy, the Occurrence and Severity of Adverse Reactions in Patients with No NCT06757114 | Second Affiliated Hospital of Xi'an Jiaotong University | — |
| Enrolling By Invitation | Sarcopenia and Cachexia in Patients With Lung Cancer NCT06730685 | Zealand University Hospital | — |
| Recruiting | Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiat NCT06688422 | The Cooper Health System | N/A |
| Recruiting | Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments NCT06448793 | Bristol-Myers Squibb | — |
| Active Not Recruiting | Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Pr NCT07215962 | Bristol-Myers Squibb | — |
| Terminated | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Mono NCT06599502 | AstraZeneca | Phase 1 |
| Active Not Recruiting | LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of M NCT06558799 | NovoCure GmbH | Phase 2 |
| Terminated | --SuPERIOR Trial-- NCT06191250 | University Health Network, Toronto | Phase 2 |
| Recruiting | Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs NCT06567015 | Pierre Fabre Medicament | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants W NCT06476808 | Bristol-Myers Squibb | Phase 1 |
| Completed | Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus NCT06735781 | Bristol-Myers Squibb | — |
| Recruiting | Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for E NCT06728865 | Li-kun Chen | Phase 2 |
| Completed | A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Receiv NCT06617390 | Daiichi Sankyo | — |
| Active Not Recruiting | Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lu NCT06162572 | Servier Bio-Innovation LLC | Phase 1 / Phase 2 |
| Not Yet Recruiting | Clinical Study of 18F-Alfatide Injection PET/CT NCT06416852 | Yantai LNC Biotechnology Singapore PTE. LTD. | Phase 3 |
| Not Yet Recruiting | Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC) NCT06454890 | Henan Cancer Hospital | Phase 1 / Phase 2 |
| Enrolling By Invitation | Liquid BiOpsy, Lung and Colon Cancer in AndaluciA NCT06997458 | Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental | — |
| Recruiting | Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With E NCT06305754 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezo NCT06332755 | LG Chem | Phase 1 |
| Recruiting | Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno- NCT06331455 | Marc de Perrot | Phase 2 |
| Withdrawn | A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING) NCT05863819 | Takeda | — |
| Completed | A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Complete NCT06267001 | Hoffmann-La Roche | Phase 3 |
| Recruiting | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors NCT06172478 | Daiichi Sankyo | Phase 2 |
| Withdrawn | A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China (ELEGANT) NCT05737849 | Takeda | — |
| Recruiting | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC NCT06162221 | Revolution Medicines, Inc. | Phase 1 / Phase 2 |
| Recruiting | Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung NCT06357598 | The Affiliated Hospital of Qingdao University | Phase 4 |
| Active Not Recruiting | A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell NCT05721950 | Takeda | — |
| Withdrawn | Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast C NCT05905341 | Pfizer | Phase 1 |
| Recruiting | Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients NCT06114108 | Swiss Cancer Institute | N/A |
| Recruiting | Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic N NCT06170788 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as NCT05920356 | Amgen | Phase 3 |
| Recruiting | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced K NCT06128551 | Revolution Medicines, Inc. | Phase 1 / Phase 2 |
| Recruiting | Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous NCT06074588 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors NCT05799274 | Radiopharm Theranostics, Ltd | Phase 1 |
| Completed | Taste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor Therapy NCT06495008 | University Medical Center Groningen | — |
| Recruiting | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors NCT06026410 | Kura Oncology, Inc. | Phase 1 |
| Active Not Recruiting | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers NCT05891171 | Arcus Biosciences, Inc. | Phase 1 |
| Active Not Recruiting | A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Smal NCT06487156 | Bristol-Myers Squibb | — |
| Recruiting | Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy NCT06667154 | Aline Fusco Fares, MD | Phase 2 |
| Recruiting | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors NCT06040541 | Revolution Medicines, Inc. | Phase 1 |
| Recruiting | Digital Lifestyle Intervention for Lung Cancer Survivors NCT05819346 | Kai-Uwe Schmitt, PhD, MEng, ICID | N/A |
| Withdrawn | Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemot NCT05791097 | Novartis Pharmaceuticals | Phase 3 |
| Recruiting | A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally A NCT05473156 | AP Biosciences Inc. | Phase 1 / Phase 2 |
| Recruiting | Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer NCT05991895 | Jinming Yu | — |
| Recruiting | a Single-arm, Single-center, Open Clinical Study NCT06431100 | Beijing Geekgene Technology Co., LTD | — |
| Active Not Recruiting | A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell NCT05801029 | AstraZeneca | Phase 2 |
| Recruiting | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Recruiting | Pembrolizumab for Advanced NSCLC and PS 2-3 NCT05589818 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Active Not Recruiting | A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY NCT05735327 | Takeda | — |
| Active Not Recruiting | PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell L NCT05553834 | Duke University | Phase 2 |
| Completed | PPIO-006 Primary Tumor Resection for IVa NSCLC NCT06232967 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | — |
| Unknown | Effect of an Oral Nutritional Supplement on Muscle Mass During Anticancer Treatment NCT05648955 | Nutricia Research | EARLY_Phase 1 |
| Recruiting | Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer NCT05765877 | Pingping Song | Phase 2 |
| Unknown | Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage NCT05661240 | Jiangsu Healthy Life Innovation Medical Technology Co., Ltd | Phase 2 / Phase 3 |
| Active Not Recruiting | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors NCT05585320 | Immuneering Corporation | Phase 1 / Phase 2 |
| Recruiting | First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutati NCT05271916 | Shanghai Chest Hospital | Phase 1 / Phase 2 |
| Completed | A Chart Review Study of Adults With Advanced NSCLC NCT05207423 | Takeda | — |
| Active Not Recruiting | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Sol NCT05462717 | Revolution Medicines, Inc. | Phase 1 |
| Completed | A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Partici NCT05419700 | Takeda | — |
| Active Not Recruiting | Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activat NCT05364073 | ArriVent BioPharma, Inc. | Phase 1 |
| Recruiting | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT05379985 | Revolution Medicines, Inc. | Phase 1 / Phase 2 |
| Recruiting | WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC NCT05351320 | Jinming Yu | Phase 2 |
| Completed | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced NCT05253807 | Incyte Corporation | Phase 2 |
| Active Not Recruiting | A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced NCT05068102 | Boehringer Ingelheim | Phase 1 |
| Recruiting | Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors NCT05176483 | Exelixis | Phase 1 |
| Terminated | Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuva NCT05088967 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Unknown | A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung C NCT05141786 | Shanghai Miracogen Inc. | Phase 2 |
| Active Not Recruiting | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours NCT05057013 | Cancer Research UK | Phase 1 / Phase 2 |
| Recruiting | Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer NCT05100069 | Takeda | — |
| Suspended | A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 NCT04908111 | Cancer Research UK | Phase 1 / Phase 2 |
| Recruiting | A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674 | Nurix Therapeutics, Inc. | Phase 1 |
| Terminated | Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Ce NCT04921358 | BeiGene | Phase 3 |
| Completed | Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom NCT04667312 | AstraZeneca | — |
| Active Not Recruiting | The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients NCT04909164 | Samsung Medical Center | — |
| Active Not Recruiting | HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or NCT04676477 | Daiichi Sankyo | Phase 1 |
| Completed | Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 S NCT04677595 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies NCT04763083 | NovalGen Ltd. | Phase 1 |
| Enrolling By Invitation | ROSE for Improved Molecular Marker Testing Via EBUS NCT04945317 | Johns Hopkins University | N/A |
| Terminated | A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or NCT04832854 | Hoffmann-La Roche | Phase 2 |
| Withdrawn | A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Fol NCT04267237 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies NCT04772989 | Arcus Biosciences, Inc. | Phase 1 |
| Terminated | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer NCT04844073 | Takeda | Phase 1 / Phase 2 |
| Unknown | Novel Light Delivery Methods for Lung Cancer Photodynamic Therapy - A Pilot Study NCT04753918 | Taoyuan General Hospital | EARLY_Phase 1 |
| Unknown | Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC NCT04905550 | Chongqing University Cancer Hospital | Phase 2 |
| Active Not Recruiting | Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Eve NCT04721015 | AbbVie | Phase 1 |
| Completed | A Study To Monitor Lung Cancer Patients Activity And Assess Performance Status Through A Wearable Device. NCT04751162 | Hoffmann-La Roche | — |
| Terminated | PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC) NCT04524195 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Predicting Response to PD-1 Checkpoint Blockade Using Deep Learning Analysis of Imaging and Clinical Data NCT05711914 | Centre Hospitalier Universitaire de Nīmes | — |
| Completed | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembr NCT04619797 | Hoffmann-La Roche | Phase 2 / Phase 3 |
| Completed | Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC NCT07053215 | The First Hospital of Hebei Medical University | N/A |
| Withdrawn | A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Particip NCT04576208 | Takeda | Phase 2 |
| Completed | Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC) NCT04563871 | Samsung Medical Center | Phase 2 |
| Completed | A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unrese NCT04513925 | Hoffmann-La Roche | Phase 3 |
| Terminated | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors NCT04424641 | Genmab | Phase 1 / Phase 2 |
| Unknown | Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC NCT04338620 | Tang-Du Hospital | Phase 2 |
| Active Not Recruiting | An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Smal NCT04189614 | AbbVie | Phase 1 |
| Terminated | Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% NCT04139317 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Prospective Clinicogenomic Program NCT04180176 | Genentech, Inc. | Phase 4 |
| Completed | A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) NCT04026412 | Bristol-Myers Squibb | Phase 3 |
| Active Not Recruiting | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors NCT04083599 | Genmab | Phase 1 / Phase 2 |
| Unknown | Comparison of Two Techniques of Uniportal VATS Lobectomies for Clinical Stage I Non-Small Cell Lung Cancer NCT03997799 | Pulmonary Hospital Zakopane | N/A |
| Active Not Recruiting | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABB NCT03893955 | AbbVie | Phase 1 |
| Completed | Osimertinib Study in Indian Patients NCT03853551 | AstraZeneca | Phase 4 |
| Completed | A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage NCT03693300 | AstraZeneca | Phase 2 |
| Terminated | DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Sm NCT03255083 | Daiichi Sankyo | Phase 1 |
| Active Not Recruiting | Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With L NCT03775486 | AstraZeneca | Phase 2 |
| Completed | A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer P NCT03725475 | AstraZeneca | — |
| Completed | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Adva NCT03735628 | Bayer | Phase 1 |
| Completed | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With A NCT03708328 | Hoffmann-La Roche | Phase 1 |
| Active Not Recruiting | Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC NCT03667820 | University of Texas Southwestern Medical Center | Phase 2 |
| Completed | The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial NCT03523702 | Montefiore Medical Center | Phase 2 |
| Terminated | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Mal NCT03549000 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer NCT03197467 | AIO-Studien-gGmbH | Phase 2 |
| Completed | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies NCT03538028 | Incyte Biosciences International Sàrl | Phase 1 |
| Completed | The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer A NCT03559647 | Hoffmann-La Roche | — |
| Unknown | Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors. NCT03447678 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Completed | A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab NCT03409458 | Promontory Therapeutics Inc. | Phase 1 / Phase 2 |
| Completed | Study of Nivolumab for Advanced Cancers in India NCT03444766 | Bristol-Myers Squibb | Phase 4 |
| Terminated | Pulmonary Rehabilitation Before Lung Cancer Resection NCT02887521 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Unknown | Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy NCT03217669 | Chao Huang | Phase 1 |
| Unknown | A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients NCT03407300 | Haining Health-Coming Biotech Co., Ltd. | Phase 2 |
| Completed | To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-l NCT05169801 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Completed | Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients Wi NCT03505515 | Bristol-Myers Squibb | — |
| Active Not Recruiting | U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer NCT03260491 | Daiichi Sankyo | Phase 1 |
| Active Not Recruiting | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) NCT03767348 | Replimune, Inc. | Phase 2 |
| Active Not Recruiting | Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for NCT03164616 | AstraZeneca | Phase 3 |
| Completed | A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients NCT02879617 | Academic Thoracic Oncology Medical Investigators Consortium | Phase 2 |
| Terminated | A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Recep NCT03082300 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Unknown | F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer NCT05468294 | Philogen S.p.A. | Phase 1 / Phase 2 |
| Completed | Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung NCT02916745 | Concordia Laboratories Inc. | Phase 1 |
| Completed | A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer NCT02840994 | Bavarian Nordic | Phase 1 |
| Completed | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors NCT02988817 | Genmab | Phase 1 / Phase 2 |
| Unknown | A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Me NCT02927340 | Massachusetts General Hospital | Phase 2 |
| Terminated | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) NCT02771626 | Calithera Biosciences, Inc | Phase 1 / Phase 2 |
| Completed | FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer NCT02839265 | Albert Einstein College of Medicine | Phase 2 |
| Completed | A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies NCT02740985 | AstraZeneca | Phase 1 |
| Terminated | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-862 NCT02698176 | Merck Sharp & Dohme LLC | Phase 1 |
| Unknown | The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation NCT02820116 | Beijing Haidian Hospital | Phase 2 |
| Unknown | A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC) NCT02714608 | Tasly Pharmaceuticals, Inc. | Phase 2 |
| Completed | FDG PET/CT in Lung Cancer Staging NCT02738398 | Abramson Cancer Center at Penn Medicine | N/A |
| Withdrawn | A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer NCT02662634 | GU Research Network, LLC | Phase 2 |
| Terminated | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small NCT02588261 | Astellas Pharma Global Development, Inc. | Phase 3 |
| Completed | Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metasta NCT02639026 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Terminated | Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases NCT02132598 | Liza Villaruz, MD | Phase 2 |
| Terminated | Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Canc NCT02642939 | Check, Jerome H., M.D., Ph.D. | Phase 2 |
| Terminated | Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Thera NCT02608528 | Abramson Cancer Center at Penn Medicine | — |
| Completed | Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) NCT02403193 | Palobiofarma SL | Phase 1 |
| Terminated | Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Posi NCT02521051 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Completed | Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC NCT02555007 | Assistance Publique Hopitaux De Marseille | Phase 1 |
| Recruiting | Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Canc NCT02448992 | Chang Gung Memorial Hospital | Phase 2 / Phase 3 |
| Completed | the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs NCT02603003 | Shanghai University of Traditional Chinese Medicine | Phase 1 |
| Unknown | Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy NCT02667743 | Shanghai Yizhong Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT NCT02456246 | University Health Network, Toronto | N/A |
| Completed | Improving Resection Rates Among African Americans With NSCLC NCT01885455 | Wake Forest University Health Sciences | N/A |
| Completed | The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Earl NCT02380196 | Abramson Cancer Center at Penn Medicine | — |
| Completed | A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tre NCT02352948 | AstraZeneca | Phase 3 |
| Completed | A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSC NCT02364362 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1 NCT07036016 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Suspended | A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) NCT02356991 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Completed | Selumetinib in Combination With Gefitinib in NSCLC Patients NCT02025114 | National Taiwan University Hospital | Phase 1 / Phase 2 |
| Completed | Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) NCT02221739 | NYU Langone Health | Phase 1 / Phase 2 |
| Completed | Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in Korea NCT02196675 | Ethicon Endo-Surgery | — |
| Completed | A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Grow NCT02113813 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Completed | A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progre NCT02066636 | Bristol-Myers Squibb | Phase 3 |
| Completed | Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer NCT02111681 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | AUY922 in Patient With Stage IV NSCLC NCT01922583 | National Taiwan University Hospital | Phase 2 |
| Completed | Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) NCT01999985 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer NCT02016872 | Memorial Sloan Kettering Cancer Center | N/A |
| Unknown | Complete Endosonographic Intrathoracic Nodal Staging of Lung Cancer Patients in Whom SABR is Considered NCT02997449 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | — |
| Completed | A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Contro NCT01951157 | PharmaMar | Phase 2 |
| Unknown | An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS NCT01964157 | Yonsei University | Phase 2 |
| Completed | Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Sma NCT01905657 | Merck Sharp & Dohme LLC | Phase 2 / Phase 3 |
| Unknown | Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients NCT01980472 | Grupo de Investigación y Divulgación Oncológica | Phase 2 |
| Completed | Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab NCT02316327 | Fundacion Clinic per a la Recerca Biomédica | Phase 4 |
| Completed | Single Arm on the Tolerability of Weekly Nab-paclitaxel NCT01702844 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Completed | Single Scope Staging of Lung Cancer With Endosonography NCT02014324 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | — |
| Terminated | Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung C NCT01741155 | Spectrum Pharmaceuticals, Inc | Phase 2 |
| Completed | Powered Echelon Device in VATS Surgery NCT01843192 | Ethicon Endo-Surgery | — |
| Completed | Powered Echelon Device in VATS Surgery NCT01808430 | Ethicon Endo-Surgery (Europe) GmbH | — |
| Recruiting | Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer NCT01720836 | Olivera Finn | Phase 1 / Phase 2 |
| Completed | A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotini NCT01712217 | Astex Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment NCT01994057 | Sun Yat-sen University | — |
| Unknown | Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation NCT01637597 | National Taiwan University Hospital | — |
| Completed | Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell NCT01594398 | Syndax Pharmaceuticals | Phase 1 |
| Unknown | Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca NCT02036359 | National Taiwan University Hospital | Phase 2 |
| Completed | Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer (NSCLC) Using Fluorescent in Situ Hybridiza NCT01620853 | Applied Spectral Imaging Ltd. | — |
| Completed | PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy NCT01666353 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Completed | Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Pr NCT01465802 | Pfizer | Phase 2 |
| Completed | A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treat NCT01454934 | Eisai Inc. | Phase 3 |
| Terminated | Nitroglycerin in Non-small Cell Lung Cancer NCT01210378 | Maastricht Radiation Oncology | Phase 2 |
| Completed | Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer NCT01498562 | Yonsei University | Phase 2 |
| Completed | Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR) NCT01463423 | Stanford University | N/A |
| Terminated | A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer NCT01574222 | VA Office of Research and Development | Phase 1 |
| Completed | Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer NCT01438307 | University of Alabama at Birmingham | Phase 2 |
| Completed | Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) NCT01323062 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Completed | Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors NCT01336842 | University of California, Davis | Phase 1 |
| Completed | A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer NCT01874678 | TTY Biopharm | N/A |
| Withdrawn | STEREOtactic Radiation and Chemotherapy in Lung Cancer (STEREO) NCT01300299 | University of Louisville | N/A |
| Completed | Pemetrexed in Advanced Non-small Cell Lung Cancer NCT01193959 | Armando Santoro, MD | — |
| Completed | Study of PX-866 and Docetaxel in Solid Tumors NCT01204099 | Cascadian Therapeutics Inc. | Phase 1 / Phase 2 |
| Unknown | e- Ab Sensor-based Real-time Detection of Mutant EGFR in Clinical Specimens From Patients of Non-small Cell Lu NCT01359436 | National Taiwan University Hospital | N/A |
| Terminated | A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Chan NCT00971191 | Pfizer | Phase 1 |
| Completed | Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers NCT01005797 | Medical University of South Carolina | Phase 1 |
| Unknown | A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non- NCT01028729 | Simcere Pharmaceutical Co., Ltd | Phase 4 |
| Terminated | Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lu NCT00850577 | Bristol-Myers Squibb | Phase 2 |
| Completed | Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer NCT00821951 | Yale University | Phase 1 |
| Terminated | Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patient NCT00807170 | Sanofi | Phase 1 |
| Completed | Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC NCT01282437 | Maastricht Radiation Oncology | Phase 3 |
| Withdrawn | Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent Chemoradiation (ChemoRT) for NCT00818714 | University of Maryland, Baltimore | Phase 1 |
| Completed | Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-s NCT00820755 | Merck KGaA, Darmstadt, Germany | Phase 3 |
| Terminated | Immunization of Patients With Non Small Cell Lung Cancer (NSCLC) NCT00793208 | Theresa Whiteside, PhD | Phase 1 |
| Completed | Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Ad NCT00770588 | AstraZeneca | Phase 4 |
| Completed | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients NCT01134250 | Philogen S.p.A. | Phase 1 / Phase 2 |
| Completed | Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer NCT00683904 | R-Pharm | Phase 1 |
| Unknown | Tarceva Italian Lung Optimization tRial NCT00637910 | Fatebenefratelli and Ophthalmic Hospital | Phase 3 |
| Completed | Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) NCT00517790 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Completed | Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer NCT00323869 | Stanford University | Phase 2 |
| Completed | Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC NCT00492206 | University of Pittsburgh | Phase 2 |
| Unknown | Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004 NCT00285675 | Novacea | Phase 2 |
| Completed | Phase 2 Trial of Bevacizumab in Combination With Pemetrexed NCT00227019 | Heather Wakelee | Phase 2 |
| Completed | An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin NCT00274443 | Celgene | Phase 2 |
| Completed | Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (F NCT00148798 | Merck KGaA, Darmstadt, Germany | Phase 3 |
| Completed | Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib NCT00820417 | Harrison Clinical Research | Phase 1 |
| Completed | Outcome of Patients With Lung Masses Who Are Treated With Radiofrequency Ablation (RFA) NCT00641238 | State University of New York - Upstate Medical University | — |
| Available | Expanded Access to Telisotuzumab Vedotin NCT04830202 | AbbVie | — |
| No Longer Available | Managed Access Programs for LDK378, Ceritinib NCT05100134 | Novartis Pharmaceuticals | — |
| Available | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory App NCT06751524 | Agenus Inc. | — |
| Approved For Marketing | Expanded Access Use of Cemiplimab in Patients With Solid Tumors NCT06132191 | Regeneron Pharmaceuticals | — |
| Approved For Marketing | Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further NCT00683306 | AstraZeneca | — |
| No Longer Available | Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC NCT01947608 | Novartis Pharmaceuticals | — |